Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates

BACKGROUND: Sorafenib has been recommended as the first-line treatment and shown to prolong the median overall survival (OS) of patients with advanced unresectable hepatocellular carcinoma (HCC). Recently, a growing number of earlier studies showed the application of radiofrequency ablation (RFA) pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lei, Zhang, Qian, Geng, Jie, Li, Songlun, Zhao, Shoujie, Zhang, Xiangnan, Hu, Jie, Feng, Dayun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290551/
https://www.ncbi.nlm.nih.gov/pubmed/32566610
http://dx.doi.org/10.21037/atm.2020.03.71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290551/
https://www.ncbi.nlm.nih.gov/pubmed/32566610
http://dx.doi.org/10.21037/atm.2020.03.71

Ejemplares similares